FDA-approval granted to Huvepharma® for feed additive CycleGuard® 500 (melengestrol acetate Type A liquid medicated article)
PEACHTREE CITY, GA (June 24, 2020) — Huvepharma® has received FDA-approval for CycleGuard® 500, a melengestrol acetate feed additive used for suppression of estrus in heifers.
Available as a Type A liquid medicated article, CycleGuard® 500 is a bio-equivalent product to MGA® and HeiferMaX®, meaning it provides the same benefits of dosage, chemical identity, potency, quality and safety to these existing melengestrol acetate brands.
CycleGuard® 500 can be used to suppress estrus in heifers intended for breeding as well as to suppress estrus among heifers fed in confinement intended for slaughter. For feedlot heifers, melengestrol acetate is also proven to increase rate of weight gain and improve feed efficiency. CycleGuard® 500 must be mixed with other feeds when fed and be fed according to label directions.
“We are excited to bring more products to the U.S. cattle industry as we continue to rapidly expand our Huvepharma portfolio,” notes Glen Wilkinson, president of Huvepharma U.S. He adds, “Huvepharma is focused on offering quality product choices and technical expertise to livestock producers and feeders to aid the industry in enhancing production and efficiency. CycleGuard® 500 is one more tool available toward that effort.”
Throughout the U.S., Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information and complete labeling information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883 or visit www.huvepharma.us.
IMPORTANT SAFETY INFORMATION: CYCLEGUARD® 500 (melengestrol acetate Type A liquid medicated article): Not effective in steers or spayed heifers. Withdrawal periods of three to five days or more should be avoided to prevent the possibility that the heifers may come into estrus (heat) at loading time. When used in heifers intended for breeding, do not exceed 24 days. A reduced conception rate can be expected within 1 to 12 days after the withdrawal of melengestrol acetate. Heifers bred on subsequent observed estruses will have normal conception rates. To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.
Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company with U.S. headquarters in Peachtree City, Georgia, Huvepharma is based in Sofia, Bulgaria. Learn more about Huvepharma and its products at https://huvepharma.us/.
Huvepharma is a registered trademark of Huvepharma EOOD.
Huvepharma, Cycleguard is a registered trademarks of Huvepharma EOOD.
MGA® is a registered trademark of Zoetis Services LLC.
HeiferMaX® is a registered trademark of Elanco US Inc.
For an optimal experience please rotate your device to portrait mode
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.